EZH2 and follicular lymphoma: Tazemestat, an EZH2 inhibitor that has shown superior methyltransferase activity in EZH2-mutant versus wild-type Follicular Lymphoma (FL) in early clinical trials, has also been granted accelerated approval by the FDA for the treatment of R/R FL.